Harbour Biomed Therapeutics

Harbour BioMed is a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in oncology and immunology. The company leverages its proprietary Harbour Mice® platforms to generate fully human monoclonal antibodies, including heavy chain only antibodies (HCAb) and bispecific immune cell engagers (HBICE®). Its lead candidate, batoclimab, is a potential best-in-class FcRn inhibitor being developed for multiple autoimmune diseases. Harbour BioMed operates a platform-driven business model, collaborating with global pharmaceutical companies and academic institutions to accelerate drug discovery. The company is headquartered in Cambridge, MA, with significant R&D and manufacturing operations in China and the Netherlands.